Handelsbanken Fonder AB Sells 31,871 Shares of Pfizer Inc. $PFE

Handelsbanken Fonder AB lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,366,190 shares of the biopharmaceutical company’s stock after selling 31,871 shares during the period. Handelsbanken Fonder AB’s holdings in Pfizer were worth $58,918,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Gables Capital Management Inc. raised its stake in shares of Pfizer by 1.4% during the fourth quarter. Gables Capital Management Inc. now owns 36,611 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 500 shares in the last quarter. Hartford Funds Management Co LLC raised its stake in shares of Pfizer by 14.5% during the fourth quarter. Hartford Funds Management Co LLC now owns 36,230 shares of the biopharmaceutical company’s stock valued at $902,000 after acquiring an additional 4,599 shares in the last quarter. Csenge Advisory Group raised its stake in shares of Pfizer by 11.6% during the fourth quarter. Csenge Advisory Group now owns 152,390 shares of the biopharmaceutical company’s stock valued at $3,795,000 after acquiring an additional 15,809 shares in the last quarter. Profund Advisors LLC increased its holdings in Pfizer by 19.7% during the fourth quarter. Profund Advisors LLC now owns 102,174 shares of the biopharmaceutical company’s stock valued at $2,544,000 after buying an additional 16,785 shares during the period. Finally, ProShare Advisors LLC increased its holdings in Pfizer by 7.2% during the fourth quarter. ProShare Advisors LLC now owns 1,155,129 shares of the biopharmaceutical company’s stock valued at $28,763,000 after buying an additional 77,325 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Wolfe Research reissued an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday. Morgan Stanley lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, April 10th. Citigroup lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.84.

Pfizer Price Performance

NYSE PFE opened at $25.31 on Tuesday. The firm’s fifty day simple moving average is $26.96 and its two-hundred day simple moving average is $26.20. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 12-month low of $22.64 and a 12-month high of $28.75. The firm has a market capitalization of $144.22 billion, a P/E ratio of 19.32 and a beta of 0.35.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.